In January 2008, we initiated preclinical development of AN2898, an anti-inflammatory compound with a similar mechanism of action to that of AN2728, but which we believe may have broader activity. Depending on the results of our preclinical studies, AN2898 may be evaluated clinically as a topical treatment in psoriasis, atopic dermatitis or other topical antifungal indications.